Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 86 Days Inventory is 182.91 as of Dec. 2025, which is 62% above its 10-year median of 113.03. GuruFocus rates LJUIF with a GF Score™ of 86/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 922 Drug Manufacturers companies, SSY Group ranks worse than 53.69% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). SSY Group's Average Total Inventories for the
six
months ended in Dec. 2025 was $151.7 Mil. SSY Group's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $151.4 Mil.
Hence, SSY Group's Days Inventory for the
six
months ended in Dec. 2025 was 182.91.
The historical rank and industry rank for SSY Group's Days Inventory or its related term are showing as below:
LJUIF'
s Days Inventory Range Over the Past 10 Years
Min: 89.47 Med: 113.03 Max: 173.92
Current: 173.92
During the past 13 years, SSY Group's highest Days Inventory was 173.92. The lowest was 89.47. And the median was 113.03.
LJUIF's Days Inventory is ranked worse than 53.69% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.58
vs LJUIF: 173.92
SSY Group's Days Inventory
increased
from Dec. 2024 (149.72) to Dec. 2025 (182.91).
It might indicate that SSY Group's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
SSY Group's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SSY Group's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.58.
SSY Group (OTCPK:LJUIF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
SSY Group's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SSY Group's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
SSY Group Days Inventory Related Terms
SSY Group Days Inventory Historical Data
* Premium members only.
The historical data trend for SSY Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where SSY Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Days Inventory of 182.91 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on SSY Group and its competitors. This is 62% above median its historical median of 113.03. Over the past decade, SSY Group's Days Inventory has ranged from 89.47 to 173.92. According to the industry distribution chart, SSY Group ranks #495 out of 922 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is SSY Group's Days Inventory too high?
SSY Group's current Days Inventory of 182.91 is 62% above median its 10-year median of 113.03. Over the past 10 years, this metric has ranged from a low of 89.47 to a high of 173.92. The Drug Manufacturers industry median Days Inventory is 164.58. SSY Group's value of 182.91 is 11.1% above this industry median. Based on the distribution chart, SSY Group ranks #495 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #495 out of 922 companies for Days Inventory. This places SSY Group in the lower half of its industry. The industry median Days Inventory is 164.58. SSY Group's value of 182.91 is 11.1% above this benchmark. Historically, SSY Group's own Days Inventory has ranged from 89.47 to 173.92 over the past decade. While the company's 10-year median is 113.03 vs. the industry median of 164.58, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.58, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Days Inventory of 182.91 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Days Inventory is 182.91, which is 62% above median its own 10-year median of 113.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Days Inventory of 182.91. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Days Inventory is 182.91, which is 62% above median its 10-year median of 113.03 and 11.1% above the Drug Manufacturers industry median of 164.58. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For SSY Group (LJUIF), the current Days Inventory is 182.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Days Inventory: 182.91 (62% above median its 10-year median of 113.03)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 11.1% above the Drug Manufacturers median (#495 of 922)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for LJUIF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
